Cardinal Health secured distribution rights for Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-1 blocker, under item number 6055347, expanding its critical-care drug portfolio to hospitals nationwide. This agreement positions Cardinal to capture additional revenue from AOP Health’s Rapiblyk sales through its purchasing channels.